True Wealth Design’s Arcutis Biotherapeutics ARQT Stock Holding History

True Wealth Design’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.19K	Buy	83 +3	+4%	+$78	﹤0.01%	1647
2026 Q2	$2.1K	Hold	80	–	–	﹤0.01%	1672
2026 Q1	$1.89K	Hold	80	–	–	﹤0.01%	1570
2025 Q4	$2.32K	Hold	80	–	–	﹤0.01%	1397
2025 Q3	$1.51K	Buy	+80	New	+$1.26K	﹤0.01%	1586
2025 Q2	–	Sell	-9	Closed	-$141	–	2585
2025 Q1	$141	Buy	+9	New	+$127	﹤0.01%	2087
2024 Q4	–	Sell	-111	Closed	-$1.03K	–	1364
2024 Q3	$1.03K	Buy	+111	New	+$1.09K	﹤0.01%	967

Other funds holding ARQT

Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

MWS

MFA Wealth Services Thousand Oaks, California $169M AUM 13.45% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

NVWM LLC Yardley, Pennsylvania $533M AUM 27.53% 1-Year Est. Return

TCM

Triumph Capital Management Denver, Colorado $573M AUM 15.32% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

True Wealth Design's ARQT Position: Q3 2026 in Review

True Wealth Design increased its Arcutis Biotherapeutics (ARQT) stake by 3.8% in Q3 2026, buying an estimated $78 and bringing the position to 83 shares worth $2.19K. The position accounts for ﹤0.01% of the portfolio, ranked #1647.

True Wealth Design first reported a position in ARQT in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.32K in Q4 2025. 16 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

True Wealth Design held 83 shares of Arcutis Biotherapeutics worth $2.19K as of Q3 2026.
True Wealth Design bought 3 Arcutis Biotherapeutics shares in Q3 2026, an estimated $78.
Arcutis Biotherapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #1647 holding.
True Wealth Design first reported a position in Arcutis Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
True Wealth Design's Arcutis Biotherapeutics position peaked at $2.32K in Q4 2025.
16 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.